XML 36 R28.htm IDEA: XBRL DOCUMENT
v3.23.3

Revenues (Tables) | 9 Months Ended
--- | ---
Sep. 30, 2023
Revenue from Contract with Customer [Abstract] |
Disaggregation of revenue by product and by geographic area | Revenues were as follows (in millions):
|  | Three months ended September 30,
|  | 2023 |  | 2022
|  | U.S. |  | ROW |  | Total |  | U.S. |  | ROW |  | Total
Prolia |  | $ | 673 |  |  | $ | 313 |  |  | $ | 986 |  |  | $ | 590 |  |  | $ | 272 |  |  | $ | 862 |
ENBREL |  | 1,026 |  |  | 9 |  |  | 1,035 |  |  | 1,086 |  |  | 20 |  |  | 1,106 |
XGEVA |  | 374 |  |  | 145 |  |  | 519 |  |  | 363 |  |  | 132 |  |  | 495 |
Otezla |  | 462 |  |  | 105 |  |  | 567 |  |  | 529 |  |  | 98 |  |  | 627 |
Repatha |  | 183 |  |  | 223 |  |  | 406 |  |  | 142 |  |  | 167 |  |  | 309 |
Nplate |  | 322 |  |  | 97 |  |  | 419 |  |  | 162 |  |  | 126 |  |  | 288 |
KYPROLIS |  | 231 |  |  | 118 |  |  | 349 |  |  | 217 |  |  | 101 |  |  | 318 |
Aranesp |  | 107 |  |  | 216 |  |  | 323 |  |  | 128 |  |  | 230 |  |  | 358 |
EVENITY |  | 214 |  |  | 93 |  |  | 307 |  |  | 136 |  |  | 65 |  |  | 201 |
Other products(1) |  | 1,099 |  |  | 538 |  |  | 1,637 |  |  | 1,113 |  |  | 560 |  |  | 1,673 |
Total product sales(2) |  | $ | 4,691 |  |  | $ | 1,857 |  |  | 6,548 |  |  | $ | 4,466 |  |  | $ | 1,771 |  |  | 6,237 |
Other revenues |  |  |  |  |  | 355 |  |  |  |  |  |  | 415 |
Total revenues |  |  |  |  |  | $ | 6,903 |  |  |  |  |  |  | $ | 6,652 |
|  | Nine months ended September 30,
|  | 2023 |  | 2022
|  | U.S. |  | ROW |  | Total |  | U.S. |  | ROW |  | Total
Prolia |  | $ | 1,987 |  |  | $ | 954 |  |  | $ | 2,941 |  |  | $ | 1,783 |  |  | $ | 853 |  |  | $ | 2,636 |
ENBREL |  | 2,645 |  |  | 37 |  |  | 2,682 |  |  | 2,965 |  |  | 54 |  |  | 3,019 |
XGEVA |  | 1,145 |  |  | 440 |  |  | 1,585 |  |  | 1,122 |  |  | 408 |  |  | 1,530 |
Otezla |  | 1,251 |  |  | 308 |  |  | 1,559 |  |  | 1,366 |  |  | 306 |  |  | 1,672 |
Repatha |  | 592 |  |  | 626 |  |  | 1,218 |  |  | 461 |  |  | 502 |  |  | 963 |
Nplate |  | 744 |  |  | 347 |  |  | 1,091 |  |  | 474 |  |  | 364 |  |  | 838 |
KYPROLIS |  | 699 |  |  | 354 |  |  | 1,053 |  |  | 626 |  |  | 296 |  |  | 922 |
Aranesp |  | 345 |  |  | 698 |  |  | 1,043 |  |  | 397 |  |  | 676 |  |  | 1,073 |
EVENITY |  | 570 |  |  | 272 |  |  | 842 |  |  | 376 |  |  | 186 |  |  | 562 |
Other products(1) |  | 3,424 |  |  | 1,639 |  |  | 5,063 |  |  | 3,379 |  |  | 1,655 |  |  | 5,034 |
Total product sales(2) |  | $ | 13,402 |  |  | $ | 5,675 |  |  | 19,077 |  |  | $ | 12,949 |  |  | $ | 5,300 |  |  | 18,249 |
Other revenues |  |  |  |  |  | 917 |  |  |  |  |  |  | 1,235 |
Total revenues |  |  |  |  |  | $ | 19,994 |  |  |  |  |  |  | $ | 19,484 |
____________ (1) Consists of product sales of our non-principal products as well as sales in prior periods of our divested Bergamo and Gensenta subsidiaries. (2) Hedging gains and losses, which are included in product sales, were not material for the three and nine months ended September 30, 2023 and 2022.

X
- Definition Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5 + Details
Name: | us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration